Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients - Top-Institutions - MDSpire

Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients

  • By

  • Grace Lee

  • Fridolin Haugg

  • Dennis Bontempi

  • John He

  • Danielle S. Bitterman

  • Suraj Pai

  • Christian Guthier

  • Kelly J. Fitzgerald

  • David E. Kozono

  • Benjamin H. Kann

  • Hugo J. W. L. Aerts

  • Raymond H. Mak

  • April 8, 2026

  • 0 min

Share

Top Institutions in Radiology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Thoracic Oncology
    • Pulmonary Medicine
    • Computational Biology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Surgery
    • Radiation Oncology
    • Pulmonary Medicine
    • Biomedical Informatics

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Pulmonary Medicine
    • Cancer Epidemiology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Radiation Oncology
    • Thoracic Oncology
    • Pulmonary Medicine
    • Biomedical Engineering

  • #5

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Radiation Oncology
    • Thoracic Surgery
    • Pulmonary Medicine
    • Bioinformatics

Original Source(s)

Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients

  • by Grace Lee, Fridolin Haugg, Dennis Bontempi, John He, Danielle S. Bitterman, Suraj Pai, Christian Guthier, Kelly J. Fitzgerald, David E. Kozono, Benjamin H. Kann, Hugo J. W. L. Aerts, Raymond H. Mak

  • April 8, 2026

Related Content

Correction: Strategies for Combination Therapy to Address Resistance to Immune Checkpoint Inhibitors

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Semantic CT features and differentiation model: new primary lung cancer versus metastasis after previous malignancy